Pharma BD Deal Intelligence
Failed to Achieve—Stiefel's $148M all-cash buy of Barrier Therapeutics closed in August 2008, but the lead pipeline candidate pramiconazole had already been shelved pre-close, and GSK's $2.9B acquisition of Stiefel less than a year later erased Barrier as a standalone outcome.
A modest dermatology tuck-in whose pipeline candidates died on the vine and whose fate was overtaken within a year by Stiefel's own $2.9B sale to GSK
Full analysis, sources & comparables →The $4.15 per share price represents a premium of approximately 73% to Barrier Therapeutics' average closing price... 'We believe that this transaction…
Stiefel's $4.15/share offer for Barrier represented a 135% premium over prior close, bringing three marketed dermatology products and five clinical candidates…
Stiefel completed the tender offer for Barrier Therapeutics on August 6, 2008, closing the ~$148M dermatology consolidation that united Xolegel, Vusion and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Stiefel Laboratories acquired Barrier Therapeutics for approximately $148 million via an all-cash tender offer at $4.15 per share, a roughly 48-73% premium depending on the reference period. The deal brought Barrier's marketed dermatology products (including Xolegel, Vusion, and Solage) and a pipeline of clinical candidates into Stiefel's existing dermatology franchise; the transaction closed August 6, 2008 after HSR clearance.
A modest dermatology tuck-in whose pipeline candidates died on the vine and whose fate was overtaken within a year by Stiefel's own $2.9B sale to GSK
Assessment window: 15yr post-close.
Therapeutic dermatology covers chronic and acute skin conditions including seborrheic dermatitis (~5.9% US adult prevalence), candidal diaper dermatitis, solar lentigines, onychomycosis, acne and psoriasis. The category is fragmented across topical antifungals, retinoids, corticosteroids and biologics, with brand competition driven by formulation differentiation and prescriber relationships.
At deal-time (June 23 2008 signing; closed August 6 2008) Barrier Therapeutics marketed three US Rx products: Xolegel (ketoconazole gel) for seborrheic dermatitis, Vusion (miconazole/zinc oxide/petrolatum) for candidal diaper dermatitis, and Solage (mequinol/tretinoin) for solar lentigines, plus five clinical candidates spanning onychomycosis, psoriasis, acne and acute fungal infections (FierceBiotech, BioSpace, GenEngNews). Stiefel paid $4.15/share cash (~$148M), a 135% premium over the prior close, and the strategic logic was straightforward bolt-on: Stiefel was the largest pure-play global dermatology company and Barrier's portfolio plugged directly into its derm sales force without overlap with Stiefel's anti-acne and rosacea franchises (Duac, MetroGel, Olux). Competing therapies included Pfizer/Janssen's azole topicals, Galderma's Differin/Epiduo, Medicis acne portfolio, Novartis Lamisil for onychomycosis and Sandoz/Taro generics. The deal mattered because it consolidated the small-cap therapeutic derm segment and was followed less than a year later by GSK's $2.9B acquisition of Stiefel itself (April 2009) - making Barrier's pipeline part of GSK's derm franchise. Source: GenEngNews coverage.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Stiefel Laboratories / Barrier Therapeutics, Inc. (this deal) | 2008 | $148M | 37 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| LEO Pharma A/S / AstraZeneca PLC | 2016 | $1.1B | 80 |
← Browse all deals · How we score deals
More: 2008 deals · Dermatology deals